Last reviewed · How we verify
CHLORPHENIRAMINE
Chlorpheniramine is a marketed antihistamine used primarily for relieving hay fever symptoms, with a key composition patent expiring in 2028. Its key strength lies in its well-established mechanism of selectively blocking histamine H1 receptors, effectively reducing allergy symptoms. However, it faces significant competition from less sedating and longer-lasting alternatives such as Cetirizine (Pfizer), Loratadine (Schering-Plough), and Fexofenadine (Sanofi).
At a glance
| Generic name | CHLORPHENIRAMINE |
|---|---|
| Also known as | chlorphenamine |
| Drug class | Antihistamine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Hay Fever Symptoms Relief
- Upper Respiratory Allergies Symptoms Relief
Common side effects
Drug interactions
- Alcohol
- Sedatives
- Monoamine oxidase inhibitors (MAOIs)
Key clinical trials
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer (PHASE2)
- Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection (PHASE2)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHLORPHENIRAMINE CI brief — competitive landscape report
- CHLORPHENIRAMINE updates RSS · CI watch RSS